Janus Henderson Group PLC 89bio, Inc. Transaction History
Janus Henderson Group PLC
- $187 Billion
- Q3 2024
A detailed history of Janus Henderson Group PLC transactions in 89bio, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 15,158,218 shares of ETNB stock, worth $121 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
15,158,218
Previous 13,276,110
14.18%
Holding current value
$121 Million
Previous $106 Million
5.48%
% of portfolio
0.06%
Previous 0.06%
Shares
12 transactions
Others Institutions Holding ETNB
# of Institutions
158Shares Held
108MCall Options Held
73.6KPut Options Held
1.19M-
Ra Capital Management, L.P. Boston, MA14.2MShares$113 Million1.46% of portfolio
-
Suvretta Capital Management, LLC New York, NY7.99MShares$63.5 Million2.33% of portfolio
-
Rtw Investments, LP New York, NY7.38MShares$58.7 Million0.87% of portfolio
-
Black Rock Inc. New York, NY7.02MShares$55.8 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA6.81MShares$54.2 Million1.6% of portfolio
About 89bio, Inc.
- Ticker ETNB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,484,500
- Market Cap $370M
- Description
- 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...